Biocept (Biocept) Accounts Payable & Accrued Expense : $3.00 Mil (As of Jun. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Biocept Accounts Payable & Accrued Expense?

Biocept's quarterly accounts payable & accrued expense declined from Dec. 2022 ($2.97 Mil) to Mar. 2023 ($2.35 Mil) but then increased from Mar. 2023 ($2.35 Mil) to Jun. 2023 ($3.00 Mil).

Biocept's annual accounts payable & accrued expense declined from Dec. 2020 ($10.66 Mil) to Dec. 2021 ($9.30 Mil) and declined from Dec. 2021 ($9.30 Mil) to Dec. 2022 ($2.97 Mil).

Biocept Accounts Payable & Accrued Expense Historical Data

The historical data trend for Biocept's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept Accounts Payable & Accrued Expense Chart

Biocept Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

3.27

3.37

10.66

9.30

2.97

Biocept Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															6.78	4.47	2.97	2.35	3.00

Biocept Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Biocept (Biocept) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (OTCPK:BIOCQ) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

9955 Mesa Rim Road, San Diego, CA, USA, 92121

Website

https://www.biocept.com

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Executives

Robert Walsh	officer: VP, Controller	9955 MESA RIM ROAD, SAN DIEGO CA 92121
Quyen Thi Dao-haddock	director	C/O: PRESIDIO PROPERTY TRUST, INC., 1282 PACIFIC OAKS PLACE, ESCONDIDO CA 92029
Philippe Marchand	officer: Chief Operations Officer	C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Darrell Taylor	officer: Sr. V.P., General Counsel	C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
David F Hale	director, officer: EXECUTIVE CHAIRMAN	1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Antonino Morales	director	C/O BICOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Linda M Rubinstein	director	25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Samuel D Riccitelli	director	2850 FRONTIER DR., WARSAW IN 46582
Michael C Dugan	officer: Chief Med Off & Med. Director	2211 MICHIGAN AVE, SANTA MONICA CA 90404-3900
Dunn Cory	officer: Sr. VP Corp. Development	C/O BIOCEPT, INC., 5810 NANCY RIDGE DR., # 150, SAN DIEGO CA 92121
Edwin Hendrick	officer: SVP, Chief Commercial Officer	2010 MAIN STREET, SUITE 600, IRVINE CA 92614
Michael J Terry	officer: Sr VP Comm. Operations
Marsha Alpert Chandler	director	7863 ENTRADA ANGELICA, SAN DIEGO CA 92127
Michael W. Nall	director, officer: CEO AND PRESIDENT	4 WOODHAVEN DRIVE, LAGUNA NIGUEL CA 92677
Timothy Kennedy	officer: CFO, Sr V.P. Operations & Sec.	5810 NANCY RIDGE DRIVE, SUITE 150, SAN DIEGO CA 92121